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IFNγIt has beenwidely reported that T cells are capable of inﬂuencing osteoclast formation and bone remodelling, yet
relatively little is known of the reciprocal effects of osteoclasts for affecting T cell function and/or activity. In this
study we investigated the effects of human osteoclasts on the function of γδ T cells, a subset of non-CD4+ T cells
implicated in a variety of inﬂammatory disease states. γδ T cells and CD4+ T cells were isolated from peripheral
blood of healthy volunteers and were co-cultured with autologous mature osteoclasts (generated by treatment
with M-CSF and RANKL) before phenotypical and functional changes in the T cell populations were assessed.
Macrophages, osteoclasts, and conditionedmedium derived frommacrophages or osteoclasts induced activation
of γδ T cells, as determined by the expression of the early activationmarker CD69. TNFαwas amajormediator of
this stimulatory effect onγδ T cells. Consistentwith this stimulatory effect, osteoclasts augmentedproliferation of
IL-2-stimulated γδ T cells and also supported the survival of unstimulated γδ and CD4+ T cells, although these
effects required co-culture with osteoclasts. Co-culture with osteoclasts also increased the proportion of γδ T
cells producing IFNγ, but did not modulate IFNγ or IL-17 production by CD4+ T cells. We provide new insights
into the in vitro interactions between human γδ T cells and osteoclasts/macrophages, and demonstrate that os-
teoclasts or their precursors are capable of inﬂuencing γδ T function both via the release of soluble factors and
also through direct cell–cell interactions.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Interactions between the immune system and bone have been a
subject of intensive research interest in recent years, with a focus on
how activated immune cells, such as T cells, affect the formation and ac-
tivity of bone-resorbing osteoclasts both in vitro and in vivo [1–6]. Such
interactions are thought to play a crucial role in the enhanced bone and
joint destruction observed in chronic autoimmune diseases such as
rheumatoid arthritis, where pro-inﬂammatory cytokines especially
TNFα, derived from CD4+ T cells present in the inﬂamed synovium
[7], result in the increased formation of osteoclasts. Other important
CD4+ T cell-derived stimulatory mediators of osteoclast formation
include the critical osteoclast differentiation factor, RANKL [5,8], and
the pro-inﬂammatory cytokine IL-17 [9], which indirectly increases
the expression of RANKL on osteoblasts and stromal cells in the local
bone microenvironment. The enhanced osteoclast activity in inﬂamedr necrosis factor alpha;αMEM,
ony-stimulating factor; RANKL,
tal bovine serum; TCR, T cell re-
egulatedonactivation,normalT
n).
. This is an open access article underjoints drives the destruction of subchondral bone in the joint, resulting
in the deterioration in jointmicroarchitecture and function, a characteris-
tic feature of rheumatoid arthritis. However, while the role of solubleme-
diators has been extensively investigated in this process, the
co-localisation of T cells with osteoclasts at the endosteal bone surface
suggests that cell–cell contactmay also play an important role in the func-
tional outcome of interactions between osteoclasts and T cells in vivo [10].
Given the extensive evidence of a role of T cells for affecting osteo-
clast formation and activity, the reciprocal interactions of osteoclasts
on T cell function, particularly in vivo, are ill-deﬁned. It is now apparent
that osteoclasts themselves share properties typically associated with
specialised antigen-presenting cells, since they are capable of antigen
uptake, processing and presentation to CD4+ and CD8+ T cells [11],
and express T cell co-stimulatory molecules such as CD40 and CD80
[11,12]. Osteoclasts have also been observed to secrete a variety of
T cell-active chemokines, and have been shown to retain and recruit
T cells in vitro [12] with such interactions resulting in the modulation
of phenotype and responsiveness of CD4+ and CD8+ T cells [11–13].
Despite these well-characterised effects of osteoclasts on CD4+ and
CD8+ T cells, it is as yet unclear what effect osteoclasts have on γδ
T cells or other non-conventional T cell subsets.
In murine models of human rheumatoid arthritis, γδ T cells have
been reported to be pathogenic through marked production of IL-17the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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bone loss in chronic human inﬂammatory diseases is currently debated,
with recent studies suggesting that IL-17 production by γδ T cells does
not play a pathophysiological role in rheumatoid arthritis [10,15],
despite an elevation in their numbers in the synovial ﬂuid and the
inﬂamed synovium in rheumatoid arthritis patients [16–19]. Interest-
ingly, a recent study has reported the increased prevalence of IL-17-
producing γδ T cells in ankylosing spondylitis patients, providing the
ﬁrst evidence for a potentially pathogenic role of γδ T cells in human
autoimmune disease [20].
In this study we investigated the effects of osteoclasts (and their
monocyte/macrophage-lineage precursors) on γδ T cell function and
reveal a novel immunostimulatory effect of macrophages/osteoclasts
on γδ T cells. Osteoclast- and macrophage-derived soluble factors, par-
ticularly TNFα, were capable of inducing activation of γδ T cells, with
further stimulatory effects of osteoclasts on γδ T cell survival, prolifera-
tion and cytokine production mediated during co-culture of these cells.
This study therefore suggests a new immunostimulatory effect of mac-
rophages and osteoclasts on γδ T cells and reveals an intriguing role for
macrophages and osteoclasts in modulating the behaviour of innate
immune cells, such as γδ T cells.
Materials & methods
All chemicals were from Sigma Chemical Co. (UK) unless otherwise
stated.
Isolation of osteoclast precursors and generation of mature osteoclasts
All work with human subjects was approved by the North of
Scotland Research Ethics Committee prior to commencement of these
studies. Osteoclastswere generated as previously described [21]. Brieﬂy,
PBMCs were isolated using density-gradient separation and monocyte/
macrophage-lineage cells were culture-expanded and differentiated to
macrophages for 5–7 days in complete αMEM (containing 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 10% (v/v) FBS)
supplemented with 20 ng/ml recombinant human M-CSF (R&D
Systems). Mature osteoclasts were generated from precursors by treat-
ment with 2 ng/ml recombinant murine RANKL (R&D Systems) and
20 ng/ml M-CSF, for 5–6 days. In some experiments macrophages
were expanded in parallel cultures, supplemented with M-CSF only.
Cells were supplied with fresh cytokines every 48 h.
T cell isolation and activation
γδ T cells and CD4+ T cells were isolated from peripheral blood
mononuclear cells (PBMCs) of healthy donors using magnetic bead
separation, as previously described [21]. The purity of the isolated
T cell subsets was routinely ≥90% for γδ T cells and ≥98% for CD4+
T cells. In some experiments γδ and CD4+ T cells were activated with
anti-CD3/anti-CD28-coated T-Activator Dynabeads® (Invitrogen) at a
bead-to-cell ratio 1:1 for 24 h, or alternatively with 100 U/ml IL-2,
prior to incubation with autologous macrophages or osteoclasts.
Determination of cytokine/chemokine production by osteoclasts
Osteoclasts were differentiated as described, then cultured for 48 h
to generate conditioned medium. Cells and debris were then removed
by sequential centrifugation at 300 g and 13,000 g, prior to determina-
tion of chemokine proﬁles using a Proteome Proﬁler Human Cytokine
Array Kit, Panel A (R&D Systems), according to the manufacturer's
instructions. Brieﬂy, conditioned medium from macrophage or osteo-
clast cultures were incubated with a cocktail of supplied biotinylated
detection antibodies prior to incubation with the array. The presence
of cytokine/antibody complexes is then determined through binding
to an immobilised capture antibody present on the array andsubsequent streptavidin–horseradish peroxidase and chemilumines-
cent detection. Levels of MCP-1/CCL2, RANTES/CCL5 and IL-8/CXCL8
were quantiﬁed using a Milliplex MAP Human Cytokine/Chemokine
array (Millipore), according to the manufacturer's instructions.
Chemotaxis assay
Differentiated osteoclasts were generated and then cultured for 48 h
in serum-free medium supplemented with 20 ng/ml M-CSF and
2 ng/ml RANKL. Conditioned mediumwas harvested, centrifuged to re-
move cells and debris, and 600 μl/well was added to 24-well plates.
Serum-freemediumandmediumcontaining 10% FBS,were supplement-
ed with M-CSF and RANKL, and used as negative and positive controls,
respectively. Prior to the chemotaxis assay, γδ T cells were activated
for 12 h with 100 U/ml rhIL-2. γδ T cells were then re-suspended in
serum-free medium at 106 cells/ml and 80 μl of cell suspension was
added into Transwell inserts (8 μm pore size). γδ T cells were incubated
for 4 h at 37 °C to allow migration through the Transwell membrane.
Cells that had migrated into the bottom chamber were harvested and
quantiﬁed using ﬂow cytometric analysis on an LSRII ﬂow cytometer
(BD Biosciences) by counting an equivalent volume of cell suspension
for each sample. γδ T cell migration was expressed as the fold-change
of migrated γδ T cells relative to FBS-induced migration.
T cell activation assay
M-CSF-expanded macrophages, or differentiated osteoclasts, were
cultured in 96-well plates at a density of 104 cells/well and allowed to
adhere for 4 h, in the presence of M-CSF alone, or with M-CSF plus
RANKL, respectively. In some experiments, mature osteoclasts were
treated for 24 h with 5 ng/ml TNFα (Peprotech) and 20 ng/ml IFNγ
(R&D Systems), followed by a 24 h wash-out period (hereafter referred
to as treated osteoclasts), prior to culture in 96-well plates. Autologous
γδ T cells or CD4+ T cells (both 5 × 104) were added to cultures of
macrophages or osteoclasts for 72 h. As a positive control, γδ T cells
were cultured in the presence of 100 U/ml IL-2, and CD4+ T cells
were activated with anti-CD3/CD28-coated T-Activator Dynabeads at a
bead-to-cell ratio of 1:1.
In some experiments, γδ T cells and CD4+ T cells were cultured with
conditioned medium frommacrophage, osteoclast or treated osteoclast
cultures. To generate conditioned medium, macrophages, osteoclasts,
and osteoclasts pre-treated with TNFα and IFNγ for 24 h, were supple-
mented with fresh medium and further cultured for 48 h. Cells and
debris were then removed by sequential centrifugation at 300 g and
13,000 g, prior to addition to T cell cultures. The following neutralising
antibodies were used: monoclonal mouse anti-human TNFα antibody,
ormouse IgG1, κ isotype control (10 μg/ml— both Biolegend). Antibod-
ies were pre-incubated with conditioned medium for 30 min prior to
addition of T cells.
Following culture, γδ T cells and CD4+ T cells were harvested and la-
belled with eFluor780 ﬁxable viability dye (eBioscience), then stained
with anti-human γδ-TCR-FITC or anti-human CD4-FITC (both Beckman
Coulter), respectively, in combination with anti-human CD69-PE anti-
body (BD Biosciences). CD69 expression by viable γδ T cells or CD4+
T cells was then assessed using ﬂow cytometric analysis with an LSR II
ﬂow cytometer, and data were analysed with FlowJo software (Tree
Star Inc.).
T cell proliferation and survival assays
Mature osteoclastswere seeded in 96-well plates as per the T cell ac-
tivation assay. Autologous γδ and CD4+ T cells were labelled with 1 μM
CellTrace™ CFSE (Molecular Probes) according to the manufacturer's
instructions, and 5 × 104 T cells (plus 100 U/ml IL-2) were cultured
alone, or in thepresence of osteoclasts, for 5 days. Cultureswere supple-
mented with freshM-CSF and RANKL every 48 h to maintain osteoclast
Fig. 1. Osteoclasts produce T cell-active chemokines capable of inducing γδ T cell chemo-
taxis. A.) Conditionedmediumwas harvested from48 h cultures ofmacrophages (MΦ) or
mature osteoclasts (OC) and cytokine/chemokine proﬁles were determined using a Prote-
ome Proﬁler Human Cytokine Array Kit (R&D Systems), according to the manufacturer's
instructions. Proteins of interest are highlighted (GROα= CXCL1; IL-8 = CXCL8; MCP-
1 = CCL2). Data shown are representative of two independent experiments using condi-
tioned medium from macrophages and osteoclasts derived from two different donors.
B.) A Transwell chemotaxis assay was conducted using serum-free medium, medium
containing 10% FBS, or serum-free osteoclast conditioned medium (OC CM) as
chemoattractants. Puriﬁed γδ T cells (pre-activated with 100 U/ml IL-2 for 12 h) were
added into the Transwell inserts (8 μm pore size) and the cells were incubated for 4 h
at 37 °C. Migrated cells were harvested and quantiﬁed using ﬂow cytometric analysis.
Migration of γδ T cells is normalised to fold-change of FBS-stimulated migration. Data
shown are mean + S.E.M. using γδ T cells from four independent donors.
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tured with osteoclast conditioned medium for 5 days. γδ T cells and
CD4+ T cells were then harvested and proliferation was assessed by
quantifying CFSE ﬂuorescence using an LSRII ﬂow cytometer. Data
were analysed with FlowJo software.
To assess T cell survival in the absence or presence of osteoclasts, au-
tologous γδ T cells and CD4+ T cells were co-cultured with osteoclasts
for 5 days, at a T cell:osteoclast ratio of 5:1. In some experiments a
monoclonal mouse anti-human TNFα neutralising antibody (or respec-
tive mouse IgG1, κ isotype control— both 10 μg/ml) was used to deter-
mine the contribution of TNFα to the survival effects of osteoclasts onγδ
T cells. Antibodies were pre-incubated with osteoclasts for 30min prior
to addition of γδ T cells. γδ T cells and CD4+ T cells were then harvested
and stained with Annexin V-Paciﬁc Blue and 7-AAD (both eBioscience).
T cell apoptosis/necrosis was assessed using ﬂow cytometric analysis
performed on an LSRII ﬂow cytometer. Data were analysed with FlowJo
software.
Intracellular cytokine staining
Following co-culture of γδ and CD4+ T cells with autologous macro-
phages or osteoclasts for 3 days, T cells were harvested and stimulated
with 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 1 μg/ml
ionomycin in the presence of Golgistop reagent (BDBiosciences) for a fur-
ther 6 h.γδ T cells and CD4+ T cellswere then harvested and stainedwith
anti-human γδ-TCR-FITC or anti-human CD4-FITC, respectively, prior to
ﬁxation and permeabilisation with a Cytoﬁx/Cytoperm kit (BD Biosci-
ences). T cells were then stained using a monoclonal mouse anti-human
IFNγ-V450 antibody ormouse IgG1, κ-V450 isotype control (both BD Bio-
sciences), and monoclonal mouse anti-human-IL-17-PE or mouse IgG1-
PE isotype control (both eBiosciences). IFNγ- and IL-17-producing T
cells were then assessed using ﬂow cytometric analysis with an LSR II
ﬂow cytometer, and data were analysed with FlowJo software.
Statistical analysis
Data were analysed using the Kruskal–Wallis one-way analysis of
variance on ranks (SigmaPlot®11.0), with inter-group comparisons
analysed using the Wilcoxon matched-pairs rank test. p values ≤ 0.05
were considered statistically signiﬁcant.
Results
Chemokine and cytokine production by osteoclasts
In order to determinewhether osteoclasts produce chemokines, and
are therefore potentially capable of recruiting γδ T cells, we determined
chemokine production by osteoclasts using a Proteome Proﬁler Array.
Conditioned medium from cultures of unstimulated mature osteoclasts
contained a variety of chemokines, including MCP-1/CCL2, GROα/
CXCL1 and IL-8/CXCL8 (Fig. 1A), indicating that osteoclasts had the ca-
pacity to recruit immune cells, including T cells and NK cells (via MCP-
1/CCL2), and granulocytes (via GROα/CXCL1 and IL-8/CXCL8).
Other factors produced by unstimulated osteoclasts detected on
the array included IL-1RA, soluble ICAM-1 (sICAM-1) and Serpin E1.
We also quantiﬁed production of a variety of chemokines and detected
marked levels of MCP-1/CCL2 (753.02 ± 170.17 pg/ml), IL-8/CXCL8
(606.43 ± 44.95 pg/ml) and RANTES/CCL5 (331.81 ± 18.42 pg/ml) in
osteoclast conditioned medium, thereby further supporting the idea
that osteoclasts are capable of inﬂuencing the recruitment of a variety
of immune cells.
Osteoclasts release soluble factors capable of recruiting γδ T cells
We then sought to determine if soluble mediators released by
osteoclasts could induce themigration of γδ T cells. Due to the potentialconfounding effects of FBS present in conditionedmedium for stimulat-
ing T cell migration directly, we generated conditioned medium from
osteoclasts cultured for 48 h in the absence of serum but supplemented
withM-CSF and RANKL; conditions which did not adversely affect oste-
oclast viability as assessed by cellularmorphology (data not shown). γδ
T cells were pre-activated with 100 U/ml IL-2 for 12 h prior to addition,
since unstimulated γδ T cells had limited motility in response to FBS-
induced migration (data not shown), consistent with a previous study
of T cell chemotaxis [22]. While activated γδ T cells did not migrate
towards serum-freemedium(Fig. 1B), FBS inducedmarkedγδ T cellmi-
gration (~15–20% of input cells — data not shown). Interestingly,
serum-free osteoclast conditionedmedium also inducedmarkedmigra-
tion of γδ T cells across the Transwell membrane, comparable to that
observed with FBS, indicating that osteoclasts release soluble factors
capable of inducing the migration of γδ T cells.
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conditions
We next assessed whether osteoclasts could induce activation of
T cells, using the early activation marker CD69. When γδ T cells or
CD4+ T cells were co-cultured with osteoclasts for 3 days a signiﬁcant
increase in CD69 expression was observed in both the γδ T cell
(Fig. 2A) and CD4+ T cell populations (Fig. 2B). A non-signiﬁcant
trend for macrophages to induce CD69 expression on both γδ T cells
(Fig. 2A) and CD4+ T cells (Fig. 2B) comparable to that observed with
osteoclasts was also demonstrated. Following co-culture with treated
osteoclasts (i.e. osteoclasts pre-treated with TNFα and IFNγ for 24 h),
CD69 expression was further increased on γδ T cells, although this was
not statistically different from untreated osteoclasts. A similar further up-
regulation of CD69 expression on CD4+ T cells was also observed follow-
ing co-culture with treated osteoclasts.
Soluble factors produced by osteoclasts are sufﬁcient to activate γδ T cells
To determine if cell–cell contact was necessary for these stimulatory
effects on CD69 expressionwe cultured γδ T cells and CD4+ T cells with
conditioned medium from macrophages, osteoclasts or treated osteo-
clasts. Conditioned medium frommacrophages, osteoclasts and treated
osteoclasts all signiﬁcantly increased CD69 expression on γδ T cells to a
similar extent (Fig. 3). This was in contrast to our ﬁndings with CD4+
T cells, since conditioned medium from macrophages or untreatedFig. 2.Osteoclasts induce CD69 expression byγδ T cells and CD4+ T cells. Quantiﬁcation of CD69
culturewith autologousmacrophages (MΦ) or osteoclasts (OC), at a T-cell:osteoclast ratio of 5:1
for 24 h (Treated OC), prior to addition of T cells. Following the incubation period, both γδ an
Representative histograms showing γδ T cell (A— right panel) and CD4+ T cell (B— right pane
oclasts. Data shown are the mean + SEM of four independent experiments, performed in duplosteoclasts consistently failed to induce upregulation of CD69 on
CD4+ T cells. However, conditioned medium from treated osteoclasts
did induce a signiﬁcant increase in CD69 expression on CD4+ T cells.
Taken together, these results indicate that γδ T cell activation bymacro-
phages or osteoclasts ismediated by soluble factors and does not funda-
mentally require cell–cell contact. However, the stimulatory effect of
osteoclasts on CD4+ T cells requires co-culture conditions, suggesting
that cell–cell interactions play an important role in this process.
TNFα is a major mediator of the stimulatory effect of osteoclasts on γδ
T cells
TNFα is a potent stimulator of T cell activation and is capable of
co-stimulatory effects on T cell survival [23,24]. We therefore investi-
gated whether macrophages and osteoclasts were triggering γδ T cell
activation via production of TNFα. Using a neutralising anti-TNFα anti-
body we observed that the stimulatory effect of macrophage- and
osteoclast-derived conditioned medium on CD69 expression by γδ
T cells was signiﬁcantly reduced versus the isotype control (Fig. 4).
There was also a trend for TNFα neutralisation to diminish the stimula-
tory effects of treated osteoclast-derived conditioned medium but this
was not statistically signiﬁcant versus the isotype control. While the
stimulatory effect of conditioned medium on γδ T cell activation was
attenuated by anti-TNFα treatment, it was not abolished entirely, indi-
cating that other stimulatory factors are present in osteoclast-derived
conditioned medium that trigger γδ T cell activation.expression onγδ T cells (A— left panel) and CD4+ T cells (B— left panel) following a 3 day
. In some experiments osteoclastswere pre-treatedwith 5 ng/ml TNFα and 20 ng/ml IFNγ
d CD4+ T cells were harvested and CD69 expression determined as detailed in Section 2.
l) CD69 expression alone, or in the presence of macrophages, osteoclasts, or treated oste-
icate, from different donors. (n = 4, *p b 0.05, ***p b 0.001 compared to T cells alone).
Fig. 3.Osteoclasts induce γδ T cell activation via the release of soluble factors. (A) CD69 expression on γδ T cells and CD4+ T cells was assessed in the presence of 100% (v/v) conditioned
medium (CM) frommacrophages (MФ), osteoclasts (OC) or treated osteoclasts (Treat OC). As positive controls, γδ T cells were activated with 100 U/ml IL-2 and CD4+ T cells with anti-
CD3/CD28 Dynabeads® at a bead-to-cell ratio of 1:1. After 3 days in culture γδ T cells and CD4+ T cells were harvested and CD69 expression on viable γδ or CD4+ T cells determined as
detailed in Section 2. Data shown are the mean + SEM of three independent experiments, performed in duplicate, from individual donors (n = 3, **p b 0.01, ***p b 0.001 compared to
T cells alone). (B) Representative histograms showing CD69 expression on viable γδ T cells (upper row) and CD4+ T cells (bottom row) cultured alone or in the presence of CM.
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Followingour observation that osteoclasts induceγδ T cell activation
we then sought to determinewhether these stimulatory effects of oste-
oclasts could trigger proliferative responses in γδ T cells. Using CFSE-
labelled γδ and CD4+ T cells in co-cultures with autologous osteoclasts,
we observed no proliferative effects of autologous osteoclasts on
unstimulated γδ T cells or CD4+ T cells (Fig. 5A). However, activation
of γδ T cells with IL-2 (which induced marked upregulation of CD69
on γδ T cells — Fig. 3A) resulted in extensive proliferation of γδ T cells,
and this proliferative effect was further enhanced by co-culture with
osteoclasts (Fig. 5A). In contrast to this, CD4+ T cells did not exhibit any
proliferative responses to IL-2 alone or in co-culture with osteoclasts.
This suggests that unstimulated osteoclasts provide co-stimulatory
signals that augment IL-2-induced γδ T cell proliferation, but such co-
stimulatory signals do not confer responsiveness of CD4+ T cells to IL-2
stimulation.
We next determined if osteoclasts could inﬂuence T cell survival
by culturing γδ T cells or CD4+ T cells with autologous osteoclasts
and consequently assessing T cell viability. After 5 days, puriﬁed cul-
tures of unstimulated γδ T cells contained 42.9 ± 6.5% viable cells,
which were signiﬁcantly increased in the presence of osteoclasts
to 81.2 ± 7.1% (Figs. 5B,C). Similarly, the viability of puriﬁed CD4+
T cells was signiﬁcantly increased by the presence of osteoclasts,from 64.8± 5.5% to 89.1 ± 2.7%. This observed increase in cell viabil-
ity conferred by osteoclasts was not simply due to engulfment of ap-
optotic T cells (and a consequent increase in the apparent viability of
T cells in these co-cultures), since the recovered cell numbers from
these co-cultures did not markedly differ from the puriﬁed T cell cul-
tures alone (data not shown). This pro-survival effect of osteoclasts
on T cells was dependent on co-culture conditions, since conditioned
medium from osteoclast cultures had no protective effect on T cell
survival (data not shown), thereby suggesting that osteoclast-
derived soluble factors are themselves insufﬁcient to maintain T cell
viability.
Due to our previously observed stimulatory effects of TNFα on CD69
expression byγδ T cells and CD4+ T cells (Fig. 4A), we next investigated
if osteoclast-derived TNFαwas responsible for these pro-T cell survival
effects using co-cultures of osteoclasts and γδ T cells. Following
neutralisation of TNFα we observed no decrease in the osteoclast-
induced survival of γδ T cells (Supplemental Fig. 1), thereby suggesting
that TNFα is not a mediator of the protective effects of osteoclasts on
T cell viability.
Osteoclasts modulate cytokine production by γδ T cells but not CD4+ T cells
We have previously shown that anti-CD3/CD28-induced activation
of puriﬁed human γδ T cells results in marked production of IFNγ,
Fig. 4. TNFα is a mediator of the stimulatory effect of macrophage/osteoclast conditioned medium on γδ T cells. (A) γδ T cells were cultured with 100% (v/v) conditioned medium (CM)
from (i.)macrophages (MФ), (ii.) untreated osteoclasts (OC), or (iii.) treated osteoclasts, in the absence or presence of anti-human TNFα antibody or isotype control (both 10 μg/ml). After
3 days in culture γδ T cells and CD4+ T cells were harvested and CD69 expression on viable γδ T cells determined as detailed in Section 2. Data shown are the mean + SEM of ﬁve inde-
pendent experiments, performed induplicate, fromdifferent donors (n=5, *p b 0.05, **p b 0.01, ***p b 0.001). (B) Representative histograms showing the effect of TNFαneutralisation on
CD69 expression induced by CM in γδ T cells.
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culture with macrophages or osteoclasts inﬂuenced the production of
IFNγ or IL-17 by γδ T cells or CD4+ T cells.
Following co-culture with macrophages, osteoclasts or IFNγ/TNFα-
treated osteoclasts, T cells were non-speciﬁcally activated with PMA
and ionomycin, to stimulate intracellular cytokine production. Co-
culturewithmacrophages or osteoclasts signiﬁcantly increased the pro-
portion of IFNγ+ γδ T cells, from 49.5 ± 11.5% in puriﬁed γδ T cell cul-
tures to 67.3 ± 6.9%, or 67.4 ± 7.4%, with macrophages or osteoclasts,
respectively (Fig. 6A). A similar, although non-signiﬁcant, trend was
also observed for treated osteoclasts to increase the proportion of
IFNγ+ γδ T cells (61.0 ± 11.3%). The increase in IFNγ+ γδ T cells was
consistently associated with a decreased proportion of IL-17+ γδ
T cells, from ~0.6% in puriﬁed γδ T cell cultures to ~0.2% in co-cultures
with macrophages or osteoclasts (Fig. 6B). Interestingly, there was no
enhanced production of IFNγ following co-culture of γδ T cells with
treated osteoclasts, suggesting that exposure of osteoclasts to pro-
inﬂammatory cytokines (such as TNFα and IFNγ) does not enhance
this stimulatory effect on IFNγ production by γδ T cells.
The modulatory effect of macrophages or osteoclasts on γδ T cell-
derived cytokine production was not observed with CD4+ T cells,
since the presence of macrophages and osteoclasts did not affect the
proportion of CD4+ T cells producing IFNγ (~18 ± 6% IFNγ+), or IL-17
(~0.9% IL-17+) (Figs. 6A,B). Taken together, this data suggests that oste-
oclasts are capable of modulating γδ T cell phenotype by enhancing
their Th1-like (IFNγ-producing) bias, but have little/no effect on CD4+
T cell phenotype.Discussion
To date, numerous studies have focussed on the effects of immune
cells for affecting osteoclastogenesis (for review see [25]), while the re-
ciprocal effects of osteoclasts for affecting immune cells, particularly the
function of various T cell subsets, awaits more thorough investigation.
In this study we investigated the effects of mature human osteo-
clasts or macrophages on the function of γδ T cells, a subset of T cells
previously implicated in the pathogenesis of a variety of chronic inﬂam-
matory diseases [14,20,26,27]. Unstimulated osteoclasts were found to
produce a range of chemokines capable of inﬂuencing the recruitment
of a range of immune cells, and soluble factors produced by osteoclasts
stimulated the chemotaxis of puriﬁedγδ T cells, thereby suggesting that
osteoclasts may be capable of orchestrating immune responses in vivo.
Of particular note, and consistentwith a previous study [12], osteoclasts
produced marked quantities of MCP-1/CCL2, which has recently been
reported to be a crucial mediator of the migration of cytotoxic γδ
T cells to tumour beds in a murinemodel of melanoma [28]. The poten-
tial recruitment of γδ T cells may also involve osteoclast-derived
RANTES/CCL5, since γδ T cells express CCR5 (a receptor for RANTES),
aswell as CCR2 [29],which governs responsiveness toMCP-1/CCL2. Fur-
thermore, this study reveals that osteoclasts may also inﬂuence the mi-
gration of neutrophils to sites of excessive osteoclast activity such as
that observed in rheumatoid arthritis, since osteoclasts produced IL-8/
CXCL8 and GROα/CXCL1, which mediate neutrophil chemotaxis and
are elevated in synovial ﬂuid of rheumatoid arthritis patients [30–32].
Taken together, these studies suggest that osteoclasts play a vital role
Fig. 5. Osteoclasts augment the proliferation of activated γδ T cells and support T cell survival. (A) Representative histograms showing the effects of osteoclasts (OC) on γδ T cell prolif-
eration in the absence or presence of IL-2 (left panels); CD4+ T cell proliferation in the absence or presence of IL-2 (right panels). γδ and CD4+ T cells were labelled with 1 μM CFSE
dye prior to their incubationwith autologous osteoclasts for 5 days. γδ T cells and CD4+ T cells were harvested and their proliferationwas assessed based on dilution of CFSE ﬂuorescence
using ﬂow cytometric analysis. Data shown are from one experiment and are representative of three independent experiments, performed in duplicate, from different donors. (B) γδ and
CD4+T cellswere cultured alone or co-culturedwith autologous osteoclasts (at a T cell:OC ratio of 5:1) for 5 days. Following this period,γδ T cells and CD4+ T cellswere harvested and cell
viability assessed as detailed in Section 2. Data shown are the mean + SEM from three independent experiments, performed in duplicate, from different donors (n = 3; ***p b 0.001).
(C) Representative contour plots showing viability of T cells alone (left column) or in co-culture with osteoclasts (right column).
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inﬂammatory conditions, and would contribute to the recruitment of
γδ T cells into the inﬂamed synovium and synovial ﬂuid of rheumatoid
arthritis patients [16–19].
The exact role of γδ T cells in the synovial microenvironment of
rheumatoid arthritis patients is currently debated, with murine models
suggesting potentially pathogenic or protective roles for inﬁltrating γδ
T cells, depending on the model system used and timing of antibody-
mediated γδ T cell depletion [10,14,15,33]. Our ﬁndings that the co-
culturing of γδ T cells or CD4+ T cells with osteoclasts can induce
T cell activation suggests that the interactions of T cells with osteoclasts
in vivo could induce T cell activation. However, while close proximity
of CD4+ T cells with osteoclasts has been demonstrated in rheumatoid
arthritis patients [10], the same study failed to identify γδ T cells associ-
ated with osteoclasts, with γδ T cells localised mainly to soft tissue
structures such as synovium and tendon. Therefore, the induction of
CD4+ T cell activation through interaction with osteoclasts, particularly
osteoclasts exposed to a pro-inﬂammatory environment, may be of
functional relevance in vivo, but evidence for direct interactions of γδ
T cellswith osteoclasts in vivo is currently lacking. Despite this, ourﬁnd-
ings suggest that osteoclasts can still inﬂuence γδ T cell function in the
absence of direct cell–cell contact via the production of stimulatory
mediators (such as TNFα, which is abundant in the inﬂamed synovium
of rheumatoid arthritis patients [7,34]) in the joint microenvironment.Wealso report here that osteoclasts support bothγδ and CD4+ T cell
survival, in accordance with a recent study [12]. This survival effect ap-
pears to rely on cell–cell contact and, although the speciﬁc mechanism
remains to be elucidated, previous studies have suggested that LFA-1:
ICAM-1 and CD28:CD80 interactions are important mediators of the
survival effects of dendritic cells on CD4+ T cell survival [35]. In support
of a role for CD28 co-stimulation in mediating the survival and prolifer-
ative effects on γδ T cells, a recent study reported that murine γδ T cells
co-culturedwith antigen-presenting cells showed an increased prolifer-
ation in the presence of CD28 agonists, and antibody-mediated block-
ade of CD28-signalling prevented γδ T cell proliferation [36]. Since
CD80 and CD86 (the ligands of CD28) are expressed on osteoclasts
[11], we suggest that co-stimulation of CD28 on γδ T cells and on
CD4+ T cells may be the cell-contact-dependent mechanism responsi-
ble for the osteoclast-mediated support of γδ and CD4+ T cell survival
and IL-2-induced γδ T cell proliferation.
Our study also reveals that co-culture with macrophages or osteo-
clasts induces an enhanced Th1-like bias in γδ T cells as assessed by
IFNγ production, demonstrating that the observed macrophage/
osteoclast-induced increase in CD69 expression has a functional out-
come for γδ T cells in vitro. While the relevance of this ﬁnding requires
formal veriﬁcation in vivo, for example using animal model systems of
erosive bone diseases or human samples, our study highlights a poten-
tially intriguing capacity ofmacrophages and osteoclasts to inﬂuence γδ
Fig. 6.Macrophages and osteoclasts increase the proportion of IFNγ-producing γδ T cells. γδ T cells or CD4+ T cells were cultured alone, or in co-culture with autologous macrophages
(MФ), osteoclasts (OC) or IFNγ/TNFα-treated osteoclasts (Treated OC) at a T-cell:OC ratio of 5:1, for 3 days. γδ T cells and CD4+ T cells were then harvested, activated with 50 ng/ml
PMA and 1 μg/ml ionomycin in the presence of GolgiStop reagent, and assessed for intracellular IFNγ and IL-17 production using ﬂow cytometric analysis, as detailed in Section 2.
Gates for IFNγ+ and IL-17+ T cells were set using ﬂuorescenceminus one (FMO) and isotype controls. Data shown are themean+SEMvalues for IFNγ-producing (A.i) or IL-17-producing
(B) γδ T cells (left panels) or CD4+ T cells (right panels) from seven independent experiments from different donors for γδ T cells (n = 7; *p b 0.05) and four independent experiments
from different donors for CD4+ T cells (n = 4). A.ii) Representative contour plots of IFNγ+ γδ T cells (top panel) and CD4+ T cells (bottom panel).
187A. Pappalardo, K. Thompson / Bone 71 (2015) 180–188T cell function. This may be of particular relevance in the context
of aminobisphosphonates (N-BPs), widely-used drugs to treat diseases
of excessive osteoclast activity [37], since the major subset of γδ
T cells in human peripheral blood, Vγ9Vδ2+ T cells, are potently activat-
ed by N-BPs [38–41]. The relatively selective internalisation of N-BPs,
released from bone mineral by osteoclasts during the process of
bone-resorption, and perhaps also by bone-associated macrophages
[42] in near-proximity to resorbing osteoclasts, would therefore be-
stow osteoclasts and macrophages with an enhanced ability to activateVγ9Vδ2+ T cells, resulting in IFNγ production and potentially Vγ9Vδ2+
T cell-mediated cytotoxic effects on osteoclasts themselves, as has
recently been demonstrated in vitro [43]. While the formal demonstra-
tion of interactions between Vγ9Vδ2+ T cells and osteoclasts has yet
to be demonstrated in N-BP-treated patients in vivo, such immuno-
stimulatory effects of macrophages/osteoclasts on Vγ9Vδ2+ T cells
could potentially contribute to the increased disease-free survival of
early-stage breast cancer patients treated with the N-BP zoledronic
acid and adjuvant endocrine therapy [44–46].
188 A. Pappalardo, K. Thompson / Bone 71 (2015) 180–188Conclusion
Our work provides further evidence for a role of osteoclasts as
immunomodulatory cells, capable of affecting γδ T cell function and be-
haviour. This supports the notion that osteoclasts may play important
roles in both the recruitment and retention of immune cells, particularly
in chronic inﬂammatory diseases such as rheumatoid arthritis, through
complex mechanisms involving the release of soluble factors and cell–
cell interactions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2014.10.019.
Acknowledgments
The authors would like to acknowledge the Oliver Bird Foundation
(RHE/00092/S1 24105) (A.P.) and Arthritis Research UK (18439) (K.T.)
for funding this work, and to thank Dr Heather M. Wilson for the helpful
comments on the manuscript.
References
[1] Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, et al. IFN-gamma stimulates
osteoclast formation and bone loss in vivo via antigen-driven T cell activation.
J Clin Invest 2007;117:122–32.
[2] Li JY, Tawfeek H, Bedi B, Yang X, Adams J, Gao KY, et al. Ovariectomy disregulates os-
teoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl
Acad Sci U S A 2011;108:768–73.
[3] Robbie-Ryan M, Paciﬁci R, Weitzmann MN. IL-7 drives T cell-mediated bone loss
following ovariectomy. Ann N Y Acad Sci 2006;1068:348–51.
[4] Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated
regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-
gamma. Nature 2000;408:600–5.
[5] Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated
T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun
1999;265:144–50.
[6] Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, KurimotoM, et al. Interleukin
18 inhibits osteoclast formation via T cell production of granulocyte macrophage
colony-stimulating factor. J Clin Invest 1998;101:595–603.
[7] Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB
ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Bone 2002;30:340–6.
[8] Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate
bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
Nature 1999;402:304–9.
[9] Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17
functions as an osteoclastogenic helper T cell subset that links T cell activation and
bone destruction. J Exp Med 2006;203:2673–82.
[10] Pollinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, et al. Th17 cells, not
IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans.
J Immunol 2011;186:2602–12.
[11] Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune
systems: osteoclasts function as antigen-presenting cells and activate CD4+ and
CD8+ T cells. Blood 2010;116:210–7.
[12] Grassi F, Manferdini C, Cattini L, Piacentini A, Gabusi E, Facchini A, et al. T cell sup-
pression by osteoclasts in vitro. J Cell Physiol 2011;226:982–90.
[13] Kiesel JR, Buchwald ZS, Aurora R. Cross-presentation by osteoclasts induces FoxP3 in
CD8+ T cells. J Immunol 2009;182:5477–87.
[14] Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL. Exacerbation
of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells.
J Immunol 2007;179:5576–83.
[15] Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, et al. Gamma/
delta T cells are the predominant source of interleukin-17 in affected joints in
collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 2009;
60:2294–303.
[16] Meliconi R, Pitzalis C, Kingsley GH, Panayi GS. Gamma/delta T cells and their subpop-
ulations in blood and synovial ﬂuid from rheumatoid arthritis and spondyloarthritis.
Clin Immunol Immunopathol 1991;59:165–72.
[17] Mitogawa T, Nishiya K, Ota Z. Frequency of gamma delta T cells in peripheral blood,
synovial ﬂuid, synovial membrane and lungs from patients with rheumatoid arthri-
tis. Acta Med Okayama 1992;46:371–9.
[18] Keystone EC, Rittershaus C, Wood N, Snow KM, Flatow J, Purvis JC, et al. Elevation of
a gamma delta T cell subset in peripheral blood and synovial ﬂuid of patients with
rheumatoid arthritis. Clin Exp Immunol 1991;84:78–82.[19] Brennan FM, Londei M, Jackson AM, Hercend T, Brenner MB, Maini RN, et al. T cells
expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun 1988;
1:319–26.
[20] Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, et al. Enrichment
of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma/
delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;
64:1420–9.
[21] Pappalardo A, Thompson K. Activated gammadelta T cells inhibit osteoclast differen-
tiation and resorptive activity in vitro. Clin Exp Immunol 2013;174:281–91.
[22] Taub DD, Key ML, Clark D, Turcovski-Corrales SM. Chemotaxis of T lymphocytes on
extracellular matrix proteins. Analysis of the in vitro method to quantitate chemo-
taxis of human T cells. J Immunol Methods 1995;184:187–98.
[23] Fotin-Mleczek M, Henkler F, Hausser A, Glauner H, Samel D, Graness A, et al. Tumor
necrosis factor receptor-associated factor (TRAF) 1 regulates CD40-induced TRAF2-
mediated NF-kappaB activation. J Biol Chem 2004;279:677–85.
[24] Yokota S, Geppert TD, Lipsky PE. Enhancement of antigen- and mitogen-induced
human T lymphocyte proliferation by tumor necrosis factor-alpha. J Immunol
1988;140:531–6.
[25] Danks L, Takayanagi H. Immunology and bone. J Biochem 2013;154:29–39.
[26] Blink SE, Miller SD. The contribution of gammadelta T cells to the pathogenesis of
EAE and MS. Curr Mol Med 2009;9:15–22.
[27] Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate
lymphoid cells. Eur J Immunol 2012;42:2221–31.
[28] Lanca T, Costa MF, Goncalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective
role of the inﬂammatory CCR2/CCL2 chemokine pathway through recruitment of
type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J Immunol 2013;190:
6673–80.
[29] Brandes M, Willimann K, Lang AB, Nam KH, Jin C, Brenner MB, et al. Flexible migra-
tion program regulates gamma delta T-cell involvement in humoral immunity.
Blood 2003;102:3693–701.
[30] Koch AE, Kunkel SL, Shah MR, Hosaka S, Halloran MM, Haines GK, et al. Growth-
related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid
arthritis. J Immunol 1995;155:3660–6.
[31] Valcamonica E, Chighizola CB, Comi D, De Lucia O, Pisoni L, Murgo A, et al. Levels
of chemerin and interleukin 8 in the synovial ﬂuid of patients with inﬂammatory
arthritides and osteoarthritis. Clin Exp Rheumatol 2014;32:243–50.
[32] Wright HL, Bucknall RC, Moots RJ, Edwards SW. Analysis of SF and plasma cytokines
provides insights into the mechanisms of inﬂammatory arthritis and may predict
response to therapy. Rheumatology (Oxford) 2012;51:451–9.
[33] Peterman GM, Spencer C, Sperling AI, Bluestone JA. Role of gamma delta T cells in
murine collagen-induced arthritis. J Immunol 1993;151:6546–58.
[34] Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1
and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged
production of IL-1 alpha. Clin Exp Immunol 1988;73:449–55.
[35] Feuillet V, Lucas B, Di Santo JP, Bismuth G, Trautmann A.Multiple survival signals are
delivered by dendritic cells to naive CD4+ T cells. Eur J Immunol 2005;35:2563–72.
[36] Ribot JC, Debarros A, Mancio-Silva L, Pamplona A, Silva-Santos B. B7-CD28
costimulatory signals control the survival and proliferation of murine and human
gammadelta T cells via IL-2 production. J Immunol 2012;189:1202–8.
[37] Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of
bisphosphonates: current status. Clin Cancer Res 2006;12:6222s–30s.
[38] Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma, delta-
T-cell proliferation and activation in vitro. J Bone Miner Res 2004;19:278–88.
[39] Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K.
Peripheral blood monocytes are responsible for gammadelta T cell activation
induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol
2009;144:245–50.
[40] Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of
gammadelta T cells by aminobisphosphonates and induction of antiplasma cell ac-
tivity in multiple myeloma. Blood 2000;96:384–92.
[41] Miyagawa F, Tanaka Y, Yamashita S, Minato N. Essential requirement of antigen pre-
sentation by monocyte lineage cells for the activation of primary human gamma
delta T cells by aminobisphosphonate antigen. J Immunol 2001;166:5508–14.
[42] Chang MK, Raggatt LJ, Alexander KA, Kuliwaba JS, Fazzalari NL, Schroder K, et al.
Osteal tissue macrophages are intercalated throughout human and mouse bone lin-
ing tissues and regulate osteoblast function in vitro and in vivo. J Immunol 2008;
181:1232–44.
[43] Cui Q, Shibata H, Oda A, Amou H, Nakano A, Yata K, et al. Targeting myeloma-
osteoclast interaction with Vgamma9Vdelta2 T cells. Int J Hematol 2011;94:63–70.
[44] Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledro-
nic acid (zoledronate) for postmenopausal women with early breast cancer receiv-
ing adjuvant letrozole (ZO-FAST study): ﬁnal 60-month results. Ann Oncol 2013;
24:398–405.
[45] Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al.
Efﬁcacy of zoledronic acid in postmenopausal women with early breast cancer re-
ceiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol
2010;21:2188–94.
[46] Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S,
Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast
cancer. N Engl J Med 2009;360:679–91.
